Reports on progress identifying possible Long COVID mechanisms (viral persistence, immune dysfunction, blood clotting), while noting no treatments are yet approved. Describes fewer than 50 active clinical trials and discusses funding and drug-development barriers, including the lack of a reliable biomarker.